Anaheim, CA – October 12, 2017 - LiveWire Ergogenics, Inc. (OTC PINK: LVVV), a company focused on research partnerships, product development and commercialization of cannabinoid-based products, today announced that it has further expanded its activities in the multi-billion dollar medical marijuana industry following an acquisition of its first 3,000 square-foot, fully equipped Greenhouse.

“The purchase of this state-of-the-art, fully climate-controlled Greenhouse is an important asset and a key element of our business strategy to capture significant market share in this rapidly expanding industry. It provides an important operational synergy with our current team of horticulturists and geneticists, as previously announced,” stated Bill Hodson, CEO of LiveWire Ergogenics. “The company is confident of a profitable operation based on the growing demand and increasingly favorable legal environment for cannabis in California and our proximity to cannabis-friendly Southern California regions.”

“This first LiveWire Greenhouse will provide our horticulture experts a turnkey nursery facility to produce high quality, pesticide-free and clean genetic clones. The nursery operation is designed to produce over 75,000 medicinal-strain clones per month that will generate significant revenue for our operators. LiveWire will provide crucial management and consulting services to the operation, as well as oversee the track and trace program,” concluded Hodson.

LiveWire’s strategy includes acquiring and leasing turnkey properties, selling location specific compliance packages and offering financing solutions for select candidates in the cannabis industry. The LiveWire management will guide our experts into a legal, profitable and sustainable business by crafting business plans, design revenue models and provide compliance notifications. LiveWire does not grow, harvest or distribute marijuana that violates any local, state or federal laws.

About LiveWire Ergogenics, Inc.
LiveWire Ergogenics, Inc. (LVVV) is focused on identifying and monetizing current and future trends in the health and wellness industry. The Company is focused on establishing research partnerships to explore the application of cannabinoid-based products to target specific ailments or conditions with a large “sufferer” population for human and veterinarian applications. This includes the cloning of cannabis strains to produce positive medicinal results, dosing verification of zero pesticide products for quality brands and development and licensing of high-quality cannabinoid based products and services. The team at LiveWire Ergogenics has a passion for research and is committed to generate and implement innovative ideas and produce high-quality products that satisfy an increasing demand in this fast-growing industry.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, financial projections, statements regarding the plans and objectives of management for future operations, the development, regulatory approvals and commercialization of the Company’s products, or any of the Company’s other proposed products, systems or services.
Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and actual events may differ considerably. Factors that may cause actual results to differ materially from any projections may include, without limitation, the Company’s inability to obtain additional financing, delays in the development of its products, the impact of significant government regulation in the cannabis industry, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

EquiNet, LLC
Toll free: 877-964-6463
Direct: 858-264-6500

1600 North Kraemer Blvd.
Anaheim, CA 92806
We initiated coverage of LiveWire Ergogenics on August 16, 2017. This is our first followup with significant news. For more detail on the company please download our Research Report. There is more to come soon.
If you want to follow all other companies that we cover with more in depth research reports, go to our research site at to download the reports,
or visit for up to date news on the covered companies.
Please feel free to re-distribute the reports to your friends and colleagues.
StockWatchIndex and SWI Research (SWI) are not registered investment advisers and the information provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI has been compensated with twenty five million restricted shares (subject to the restrictions of rule 144) by the Company  for the dissemination of this and future releases and  for continuing consulting and advisory services. The included information is subject to change without notice. Please visit!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.